Measuring plasma PCSK9 may ID resistance to PCSK9 inhibitors

November 29, 2017

(HealthDay)—Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) may help assess apparent resistance to PCSK9 inhibitors, according to a research letter published online Nov. 28 in the Annals of Internal Medicine.

Michael D. Shapiro, D.O., from the Oregon Health & Science University in Portland, and colleagues describe changes in PCSK9 levels before and after PCSK9 inhibitor therapy in 17 adult patients with cardiovascular disease (14 patients) and/or familial hypercholesterolemia (nine patients). Before and three months after initiation of PCSK9 inhibitor therapy, total plasma PCSK9 levels were measured.

The researchers found that the mean baseline plasma PCSK9 level was 324 ng/mL. Within five days of their sixth self-injection, the total plasma PCSK9 levels were 2,286 ng/mL in patients with the anticipated greater-than-45-percent reduction in (LDL) levels (median seven-fold increase from baseline levels). Plasma PCSK9 levels varied, but they increased by at least 3.7-fold in 16 of the patients; pre- and post-treatment values were not overlapping for any of these patients. Two of the patients with familial hypercholesterolemia had markedly attenuated response of LDL cholesterol levels to the PCSK9 inhibitor; one of these had no change in plasma PCSK9 levels.

"We report a simple method for assessing apparent resistance by measuring total levels of plasma PCSK9 before and after treatment," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Explore further: PCSK9 increased in females, youth with type 1 diabetes

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

PCSK9 increased in females, youth with type 1 diabetes

June 20, 2017
(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) is increased in young females and youth with type 1 diabetes (T1D), according to research published online June 6 in Diabetes Care.

PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis

August 28, 2017
PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class of cholesterol lowering ...

PCSK9 monoclonal antibodies show promise in ACS

March 23, 2016
(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

PCSK9 inhibitors reduce lipoprotein (a) production

October 31, 2016
A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, ...

New lipid-lowering drugs help patients reduce LDL cholesterol

August 1, 2016
A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.

Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective

August 22, 2017
An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater ...

Recommended for you

Scientists rewrite our understanding of how arteries mend

December 13, 2017
Scientists from The University of Manchester have discovered how the severity of trauma to arterial blood vessels governs how the body repairs itself.

Deadly heart rhythm halted by noninvasive radiation therapy

December 13, 2017
Radiation therapy often is used to treat cancer patients. Now, doctors at Washington University School of Medicine in St. Louis have shown that radiation therapy—aimed directly at the heart—can be used to treat patients ...

Ultra-thin tissue samples could help to understand and treat heart disease

December 12, 2017
A new method for preparing ultra-thin slices of heart tissue in the lab could help scientists to study how cells behave inside a beating heart.

Research reveals how diabetes in pregnancy affects baby's heart

December 12, 2017
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered how high glucose levels—whether caused by diabetes or other factors—keep heart cells from maturing ...

Young diabetics could have seven times higher risk for sudden cardiac death

December 12, 2017
Young diabetics could have seven times more risk of dying from sudden cardiac arrest than their peers who don't have diabetes, according to new research.

Blood flow–sensing protein protects against atherosclerosis in mice

December 12, 2017
UCLA scientists have found that a protein known as NOTCH1 helps ward off inflammation in the walls of blood vessels, preventing atherosclerosis—the narrowing and hardening of arteries that can cause heart attacks and strokes. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.